Shots:
- Genentech has entered into a multi-year collaboration with Orionis to discover small-molecule monovalent glue drugs for novel & difficult oncology targets using Orionis’ Allo-Glue platform
- As per the deal, Orionis will receive $105M upfront & ~$2B in research, development, commercial, & sales milestones, with tiered royalties; Orionis will lead discovery & optimization, while Genentech handles later-stage preclinical & clinical development, regulatory filing, & marketing
- Allo-Glue integrates advanced chemical biology, engineered cellular assays, high-throughput automation, & AI-driven chemistry with predictive modeling & generative design to analyze millions of in-cell protein interactions
Ref: Businesswire | Image: Genentech & Orionis| Press Release
Related News:- Genentech Reports P-III (APHINITY) Trial Data of Perjeta Regimen for Early-Stage Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
